Yeah, now we dont have to read the droning sad sack posts from cold posters !
“Our 3D portfolio continues to expand with new product launches scheduled for later in 2019, as well as ongoing progress on our single piece 3D aortic valve. The next phase of our 3D product strategy is the development of the first and only single piece 3D aortic valve. Interim data from the animal feasibility study has shown this has the potential to deliver significant clinical benefits and is differentiated from other TAVR products currently available,” said Dr Bhirangi. “The 3D single piece aortic valve is unique in the industry and forms the backbone of the company’s TAVR developmental project which has been expedited. We have now confirmed that human clinical trials will commence earlier than planned,
- Forums
- ASX - By Stock
- AVR
- News: AHZ Admedus Says Cardiocel 3D And Vascucel Receives European Regulatory Approval
News: AHZ Admedus Says Cardiocel 3D And Vascucel Receives European Regulatory Approval, page-4
-
- There are more pages in this discussion • 564 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add AVR (ASX) to my watchlist
(20min delay)
|
|||||
Last
$9.91 |
Change
-0.090(0.90%) |
Mkt cap ! $209.4M |
Open | High | Low | Value | Volume |
$10.00 | $10.00 | $9.65 | $70.76K | 7.202K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 300 | $9.80 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$9.91 | 475 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 300 | 9.800 |
1 | 200 | 9.600 |
1 | 2 | 9.540 |
1 | 330 | 9.510 |
2 | 1185 | 9.500 |
Price($) | Vol. | No. |
---|---|---|
9.910 | 475 | 2 |
9.990 | 99 | 1 |
10.000 | 250 | 1 |
10.500 | 10005 | 2 |
11.000 | 5000 | 1 |
Last trade - 16.10pm 12/11/2024 (20 minute delay) ? |
Featured News
AVR (ASX) Chart |
The Watchlist
NUZ
NEURIZON THERAPEUTICS LIMITED
Michael Thurn, CEO & MD
Michael Thurn
CEO & MD
Previous Video
Next Video
SPONSORED BY The Market Online